10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs

Ten companies boasted strong double-digit gains on Wednesday, crushing a mixed broader market, as investor funds continued to pile into stocks benefiting from the booming AI sector. Five notably propelled to fresh all-time highs.

On Wall Street, only the S&P 500 and the Nasdaq finished in the green, up 0.40 percent and 0.66 percent, respectively. The Dow Jones was down by 0.04 percent.

In this article, we focus on the 10 names that led Wednesday’s charge and detail the reasons behind their gains. To come up with the list, we focused exclusively on mid-cap stocks with at least $2 billion in market capitalization and 5 million shares in trading volume.

A man analyzing stock market data. Photo by Tima Miroshnichenko on Pexels

10. Sandisk Corp. (NASDAQ:SNDK)

Sandisk rallied to a new all-time high on Wednesday, as investors took heart from a price target upgrade from three investment companies, while cheering the softening trade tensions between the US and China.

In intra-day trading, Sandisk Corp. (NASDAQ:SNDK) rallied to its highest 52-week price of $144.55 before ending the day up by 13.36 percent at $144.30 apiece.

Of the three analyses released earlier this week, Goldman Sachs gave the most bullish stance, raising its price target by 154 percent to $140 from $55 previously, while maintaining a “buy” recommendation.

Citigroup, for its part, raised its price target by 30 percent to $150 from $115 previously, similarly giving a “buy” recommendation.

Meanwhile, Wells Fargo increased its price target for Sandisk Corp. (NASDAQ:SNDK) by 130 percent to $115 from $50 previously, but was only “equal weight” on the stock.

In other news, Sandisk Corp. (NASDAQ:SNDK) was scheduled to announce the results of its first quarter earnings performance for the fiscal year 2026 on November 6, 2025.

9. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals extended its winning streak to a third straight day on Wednesday, jumping 15.28 percent to close at $6.79 apiece as investors loaded portfolios following a recently concluded major AI conference in Dubai.

On Wednesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) cofounder and CEO Chris Gibson spoke at the event, where he tackled how AI was shaping the company’s future direction, specifically, its approach to generating data, automating experiments, and using AI and machine learning for its discoveries.

Additionally, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Research and Development Officer Najat Khan is expected to take part in an upcoming virtual summit, “The State of AI in Drug Discovery” on October 29, where he and fellow Boltz-2 developers from the Massachusetts Institute of Technology will talk about the democratization of small molecule drug discovery.

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks.